#780 The Economics Behind Vaccinations w/ Dr. Peter McCullough

— Vaccine manufacturer profitability and financial incentives: Moderna projected $19.2B, Pfizer $33.5B, and J&J $2.5B in 2021 COVID-19 vaccine sales, with minimal development and marketing costs due to government funding and Emergency Use Authorization, resulting in exceptionally high profit margins.

— Conflicts of interest in public health policy: Former FDA Commissioner Scott Gottlieb now sits on Pfizer's board while appearing on CNBC; former FDA Commissioner Stephen Hahn joined Moderna's venture capital funder; the NIH co-owns a vaccine patent with Moderna.

— Suppression of early treatment in developed nations: Dr. McCullough argues wealthy nations were starved of COVID-19 early treatment options while being primed for mass vaccination, contrasting with equatorial markets that distributed treatment packets.

— Vaccine efficacy claims and Emergency Use Authorization: Pfizer remains under EUA despite claims of FDA approval; BioNTech's approved application requires post-marketing studies on myocardial injury and pregnancy safety that have not been completed.

— Vaccine effectiveness against variants: Real-world data shows only 20% effectiveness against Delta and no effectiveness against Omicron; global pandemic trends show vaccines have made no measurable impact on transmission.

— Testing expansion as profit driver: At-home COVID test prices rose from $14 to $24 due to demand; asymptomatic testing generates false positives 97% of the time and is unsupported by FDA, WHO, or CDC guidance.

— Understand the financial incentives and conflicts of interest underlying public health recommendations before accepting claims uncritically; follow the money and track which entities profit from promoted solutions.

— Demand transparency on post-market safety data and completed trials before accepting medical interventions marketed as emergency-approved; distinguish between Emergency Use Authorization and full FDA approval.

— For high-risk individuals, focus on targeted testing and treatment strategies rather than mass asymptomatic testing; recognize that widespread testing of asymptomatic populations produces false positives that undermine clinical decision-making.